TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v8i11.1431Keywords:
Chronic Kidney Disease, Diabetes Mellitus, Obese, Risk FactorAbstract
Hyperglycemia is the primary symptom of diabetes mellitus, which is a set of metabolic illnesses that can be caused by abnormalities in insulin secretion, insulin action, or both. Diabetes Mellitus (DM) is the most common form of diabetes. Chronic hyperglycemia brought on by diabetes is linked to long-term damage, dysfunction, and even failure of a number of glands, most notably the eyes, kidneys, nerves, heart, and blood arteries. 1 Because there are a variety of criteria that must be satisfied before a diagnosis of diabetes can be made, it is challenging to estimate the disease's prevalence. Diabetes-related nephropathy, also known as diabetic nephropathy or diabetic kidney disease, can affect approximately forty percent of patients who have been diagnosed with type 2 diabetes mellitus (DKD). Patients who are diagnosed with type 2 diabetes are often of an older age at the time of their diagnosis, and it is possible that these patients will develop kidney damage due to factors other than diabetes. Patients diagnosed with type 2 diabetes are at an increased risk of developing chronic kidney disease (CKD) due to a number of variables, including hypertension, a history of kidney disease, neuropathy, dyslipidemia, and substance abuse.
References
International Diabetes Federation. Diabetes. Brussels: IDF; 2017.
Evans K. Diabetic ketoacidosis: update on management. Clin Med. September 2019;19(5):396–8.
Association AD. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2019. Diabetes Care [Internet]. 7 Desember 2018;42(Supplement_1):S173–81. Tersedia pada: https://doi.org/10.2337/dc19-S015
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2016;62–9.
Soelistijo SA, Lindarto D, Decroli E, et al. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. Jakarta: PB Perkeni; 2021.
Patoulias D, Papadopoulos C, Stavropoulos K, et al. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. J Clin Hypertens. 2020;22(4):562–71.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J kidney Dis Off J Natl Kidney Found. Mei 2014;63(5):713–35.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case–control study in 13 countries. Circulation. 2014;129(9):999–1008.
Stephens JW, Brown KE, Min T. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obes Metab. April 2020;22 Suppl 1:32–45.
Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. Juni 2020;19(1):98.
Liu B, Wang Y, Zhang Y, Yan B. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Curr Top Med Chem. 2019;19(20):1818–49.
Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. Maret 2020;29(2):190–8.
Debele GR, Hajure M, Wolde HF, Yenit MK. Incidence and Predictors of Chronic Kidney Disease among Diabetes Mellitus Patients: A Retrospective Follow-Up Study at a Tertiary Health-Care Setting of Ethiopia. Diabetes, Metab Syndr Obes Targets Ther. 2021;14:4381.
Ahmed MA, Ferede YM, Takele WW. Incidence and predictors of chronic kidney disease in type-II diabetes mellitus patients attending at the Amhara region referral hospitals, Ethiopia: A follow-up study. PLoS One [Internet]. 26 Januari 2022;17(1):e0263138. Tersedia pada: https://doi.org/10.1371/journal.pone.0263138
Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, Pepió JMA, Roura P, Benito B, et al. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area. BMC Nephrol [Internet]. 2012;13(1):87. Tersedia pada: https://doi.org/10.1186/1471-2369-13-87
An L, Yu Q, Tang H, Li X, Wang D, Tang Q, et al. The Prevalence, Progress and Risk Factor Control of Chronic Kidney Disease in Chinese Adults With Type 2 Diabetes Mellitus in Primary Care [Internet]. Vol. 13, Frontiers in Endocrinology . 2022. Tersedia pada: https://www.frontiersin.org/articles/10.3389/fendo.2022.859266
Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
Wong E. Chronic Kidney Disease. Lancet. 2012;379(8911):80–165.
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121–32.
Tong X, Yu Q, Ankawi G, Pang B, Yang B, Yang H. Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results. Diabetes Ther Res Treat Educ diabetes Relat Disord. September 2020;11(9):1983–99.
Sharma SG, Bomback AS, Radhakrishnan J, Herlitz LC, Stokes MB, Markowitz GS, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. Oktober 2013;8(10):1718–24.
Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. lancet Diabetes Endocrinol. Mei 2018;6(5):361–9.
Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Prim [Internet]. 2015;1(1):15018. Tersedia pada: https://doi.org/10.1038/nrdp.2015.18
Nordheim E, Geir Jenssen T. Chronic kidney disease in patients with diabetes mellitus. Endocr Connect [Internet]. 2021;10(5):R151–9. Tersedia pada: https://ec.bioscientifica.com/view/journals/ec/10/5/EC-21-0097.xml
de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. Desember 2011;365(25):2366–76.
Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. Februari 2014;129(5):587–97.
De Cosmo S, Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, et al. Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. J Hypertens. 2016;34(10):2090–8.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Advance Research in Medical & Health Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
